Anesthesia in renal transplantation. Observations at 142 anesthetics in 50 patients

Anaesthesiological complications in renal transplantation: a retrospective study of 500 transplantations

This retrospective study consisted of 500 consecutive renal transplantations performed between September 1977 and September 1981. Preoperatively, congestive heart failure was registered in 262 cases (53.0%) and blood pressure disease in 352 cases (71.3%). The total number of patients with ischaemic heart disease was 22 (4.5%). General anaesthesia was given in 493 and regional anaesthesia in seven cases. In general anaesthesias, tubocurarine was the main relaxant and halothane the main inhalation agent used. Major complications during anaesthesia were blood pressure changes with a higher incidence of hypotension (49.6%) than hypertension (26.8%). Severe cardiac arrhythmias were rare and no intraoperative deaths occurred. One patient was successfully resuscitated in the ICU postoperatively, this being possibly related to hypoventilation caused by prolonged muscular relaxation. Other rare complications included one pneumothorax, one haemo- and hydrothorax, and two large haematomas all caused by preoperative central venous cannulation. In 69 cases (14.0%) additional neostigmine doses and in 34 cases (6.9%) naloxone was given at the end of anaesthesia. Pneumonia during the first postoperative week was recorded in 11 cases (2.2%), and occurred only in patients who received general anaesthesia. One of the three patients who died during the first week developed pneumonia postoperatively.

Enflurane anesthesia in living donor renal transplantation

Two groups of patients undergoing elective living donor renal transplantation were studied during enflurane or halothane supplemented anesthesia. The duration of anesthesia was similar in both groups. The mean administered enflurane dose was 243 vol % min; the corresponding halothane dose was 56 vol % min. In the enflurane group, the mean serum inorganic fluoride level peaked at 21.0 mumol/l 3 h after the end of anesthesia. The inorganic fluoride level in urine produced by the renal graft increased continuously, but did not peak, during the first 24 postanesthetic hours. The renal graft quickly started to function in all patients in both groups. The frequency of rejection reactions was higher in the enflurane group than in the halothane group. Serum creatinine levels decreased rapidly in both groups. Urine flow was high on the day of transplantation, but normalized on the first postanesthetic day. Renal sodium clearance decreased earlier in the enflurane group than in the halothane group. This difference was statistically significant on the first postanesthetic day. In the enflurane group, the required pancuronium dose was significantly lower than in the halothane group. In one patient in the enflurane group, the serum inorganic fluoride level increased to 37.5 mumol/l. In this patient renal tubular function may have been affected, but the change was not conclusive since a pronounced rejection of the graft became evident. Since increases in serum inorganic fluoride level approaching 75% of the threshold level for nephrotoxicity in normal kidneys may occur, enflurane should not be routinely used in anesthesia for renal transplantation.

Anaesthetic considerations in chronic renal failure

This paper discusses the anaesthetic problems presented by patients in chronic renal failure. The anaesthetic agents and techniques used in 181 patients who underwent 941 operations (including 218 renal transplants) are described.